NYSE:TEVAPharmaceuticals
Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025?
If you are wondering whether Teva Pharmaceutical Industries is still a buy after its big run, you are not alone. This stock has quickly moved from contrarian idea to front and center on many investors watchlists.
Over the last week Teva is up 4.7%. It has climbed 17.2% over the past month, and the stock is now sitting on a 39.9% gain year to date and an 80.5% rise over the last year, with a 242.8% return in 3 years and 197.6% over 5 years.
Much of this momentum reflects a shift in how the...